A clinical review of statins and cancer: Helpful or harmful?

Pharmacotherapy

Volumn 30, Issue 2, 2010, Pages 177-194

  Gonyeau, Michael J ^a   Yuen, Dayton W ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Breast cancer; Cancer; Clinical trials; Colorectal cancer; HMG CoA; Lung cancer; Neoplasm; Pleiotropic effects; Prostate cancer; Statins

Indexed keywords

ANALGESIC AGENT; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; DOLICHOL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; PROSTATE SPECIFIC ANTIGEN; ROSUVASTATIN; SIMVASTATIN;

ANGIOGENESIS; BREAST CANCER; CANCER RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COLORECTAL CANCER; DATA BASE; DISEASE ASSOCIATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; LUNG CANCER; MEDICAL LITERATURE; MEDLINE; MELANOMA; OBSERVATIONAL STUDY; PLEIOTROPY; PRESCRIPTION; PROSPECTIVE STUDY; PROSTATE CANCER; RETROSPECTIVE STUDY; REVASCULARIZATION; REVIEW; RISK ASSESSMENT; UNITED STATES;

ANTILIPEMIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; NEOPLASMS; RISK FACTORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 75849124050     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.2.177     Document Type: Review

References (72)

1. Centers for Disease Control and Prevention. National health statistics reports. National ambulatory Medicare care survey: 2006 summary. Available from http://www.cdc.gov/nchs/ data/nhsr/nhsr003.pdf. Accessed November 19, 2008.
2. Mahley RW, Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In: Brunton LL, Lazo JS, Parker KL, et al, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. Columbus, OH: McGraw-Hill Companies, Inc., 2006:933.
3. Agency for Healthcare Research and Quality. Statistical brief #205. Trends in statins utilization and expenditures for the U.S. civilian noninstitutionalized population, 2000 and 2005. Available from http://www.meps.ahrq.gov/mepsweb/data-files/publications/st205/stat205.pdf. Accessed November 26, 2008.
4. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005;114:643-7.
5. Stamm JA, Ornstein DL. The role of statins in cancer prevention and treatment. Oncology (Williston Park) 2005;19:739-54.
6. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces the levels of Alzheimer's disease β-amyloid peptide Aβ42 and Aβ40 in vitro and in vivo. Proc Acad Sci USA 2001;98:5856-61.
7. Edwards CJ, Hart DJ, Spectore TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000;355:2218-19.
8. Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 2001;77:247-53.
9. Glorioso N, Manunta P, Filigheddu F, et al. Effect of the HMGCoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34:1281-6.
10. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and nonischemic heart failure. J Am Coll Cardiol 2004;43:642-8.
11. Horwich TB, Hamilton MA, MacLellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002;8:216-24.
12. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008;336:645-51.
13. Chen CL, Huang SS, Huang JS. Cholesterol modulates cellular TGF-β responsiveness by altering TGF-β binding to TGF-β receptors. J Cell Physiol 2008;215:223-33.
14. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7:687-92.
15. Houten SM, Frenkel J, Waterham HR. Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation. Cell Mol Life Sci 2003;60:1118-34.
16. Kritchevsky SB, Kritchevsky D. Serum cholesterol and cancer risk: an epidemiologic perspective. Annu Rev Nutr 1992;12:391-416.
17. Smith PF, Grossman SJ, Gerson RJ, et al. Studies on the mechanism of simvastatin-induced thyroid hypertrophy and follicular cell adenoma in the rat. Toxicol Pathol 1991;19:197-205.
18. Lamprecht J, Wojcik C, Jakobisiak M, Stoehr M, Schrorter D, Paweletz N. Lovastatin induces mitotic abnormalities in various cell lines. Cell Biol Int 1999;23:51-60.
19. Watanabe M, Koike H, Ishiba T, Okada T, Seo S, Hirai K. Synthesis and biological activity of methane sulfonyl pyrrolesubstituted 3,4-dihydroxy-6-heptanoates: a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem 1997;5:437-44.
20. Hindler K, Cleeland CS, Rivera E, Collard CD. The role of statins in cancer therapy. Oncologist 2006;11:306-15.
21. Wejde J, Hjertman M, Carlberg M, et al. Dolichol-like lipids with stimulatory effect on DNA synthesis: substrates for protein dolichylation? J Cell Biochem 1998;71:502-14.
22. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-74.
23. Okumadu C, Dutta A. p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. J Biol Chem 2003;278:43586-94.
24. Dulak J, Jozkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets 2005;5:579-94.
25. Frick M, Dulak J, Cisowski J, et al. Statins differentially regulate vascular endothelial growth factor in endothelial and vascular smooth muscle cells. Atherosclerosis 2003;170:229-36.
26. De Four KJS, Paleolog E, Sandison A, Cohen P, Dawson PM. Does statin treatment alter VEGF and HIF expression in human colorectal cancer? An immunohistochemical (IHC) approach: lower gastrointestinal 10328 [abstract]. Br J Surg 2006;93:229.
27. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-10.
28. Brouet A, Sonveaux P, Dessy C, et al. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 2001;89:866-73.
29. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002;105:739-45.
30. Schaefer CA, Kuhlmann CR, Gast C, et al. Statins prevent oxidized low-density lipoprotein- and lysophosphatidylcholineinduced proliferation of human endothelial cells. Vasc Pharmacol 2004;41:67-73.
31. Wang IK, Lin-Shiau SY, Lin JK. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology 2000;59:245-54.
32. Kusama T, Mukai M, Iwasaki T, et al. Inhibition of epidermal growth factor - induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors. Cancer Res 2001;61:4885-91.
33. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
34. Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med 2004;229:567-85.
35. Cafforio P, Dammacco F, Gernone A, Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 2005;26:883-91.
36. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999;341:70-6.
37. Teo KK, Burton JR, Buller CR, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the simvastatin/enalapril coronary atherosclerosis trial (SCAT). Circulation 2000;102:1748-54.
38. ALLHAT Officers and Coordinators. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA 2002;288:2998-3007.
39. LaRosa JC, Grudy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
40. Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study - a randomized controlled trial. JAMA 2005;294:2437-45.
41. Amarenco P, Goldstein LB, Szarek M, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack. Stroke 2007:38:3198-204.
42. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
43. Blankenhorn DH, Azen ST, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy: the monitored atherosclerosis regression study (MARS). Ann Intern Med 1993;119:969-76.
44. Shepard J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
45. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
46. Hallvard H, Fellstrom B, Jardine AG. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomized, placebo-controlled trial. Lancet 2003;361:2024-31.
47. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-22.
48. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48.
49. Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
50. Strandberg TE, Pyorala K, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian simvastatin survival study (4S). Lancet 2004;364:771-7.
51. Sheperd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360:1623-30.
52. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
53. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Long-term follow-up of the west of Scotland coronary prevention study. N Engl J Med 2007;357:1477-86.
54. Karp I, Behlouli H, LeLorier J, Pilote L. Statins and cancer risk. Am J Med 2008;121:302-9.
55. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology 2007;18:213-19.
56. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP, Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008;17:27-36.
57. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer. Arch Intern Med 2000;160:2363-8.
58. Kaye JA, Jick H. Statin use and cancer risk in the general practice research database. Br J Cancer 2004;90:635-7.
59. Graaf MR, Beiderbeck AB, Egberts ACG, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol 2004;22:2388-94.
60. Farwell WR, Scranton RE, Lawler EV, et al. The association between statins and cancer incidence in a veteran population. J Natl Cancer Inst 2008;100:134-9.
61. Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer in humans: a large case-control study of U.S. veterans. Chest 2007;131:1282-8.
62. Cyrus-David MS, Weinberg A, Whompson T, Kadmon D. The effect of statins of serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol 2005;173:1923-5.
63. Shannon J, Tewoderos S, Garzotto M, et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005;162:318-25.
64. Platz EA, Leitzmann MF, Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006;98:1819-25.
65. Cauley JA, McTiernan A, Rodabough RJ, et al. Statin use and breast cancer: prospective results from the women's health initiative. J Natl Cancer Inst 2006;98:700-7.
66. Eliassen AH, Colditz GA, Rosner B, Willet WC, Hankinson SE. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 2005;165:2264-71.
67. Poynter JN, Gruber ST, Higgins PDR, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005;352:2184-92.
68. Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst 2007;99:32-40.
69. Hachem C, Morgan R, Johnson M, Keubeler M, El-Serag H. Statins and the risk of colorectal carcinoma: a nested casecontrol study in veterans with diabetes. Am J Gastroenterol 2009;104:1241-8.
70. El-Serag HA, Johnson ML, Hachem C, Morgana RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009;136:1601-8.
71. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA 2006;295:74-80.
72. Nainggolan L, Mulcahy N. Cancer set to overtake heart disease as top global killer. The Heart. Available from http://www.theheart.org/article/ 928501.do. Accessed March 26, 2009.